Frankfurt - Delayed Quote EUR
Tandem Diabetes Care, Inc. (TD5A.F)
15.24
-0.49
(-3.08%)
As of 8:01:16 AM GMT+2. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 19 | 19 | 22 | 22 |
| Avg. Estimate | 220.22M | 244.82M | 998.74M | 1.1B |
| Low Estimate | 212.14M | 232.54M | 985.42M | 1.08B |
| High Estimate | 222.71M | 255.35M | 1.01B | 1.14B |
| Year Ago Sales | 191.67M | 221.91M | 940.2M | 998.74M |
| Sales Growth (year/est) | 14.89% | 10.32% | 6.23% | 10.54% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| TD5A.F | -- | -- | -- | -- |
| S&P 500 | 9.62% | 4.20% | 8.36% | 13.90% |
Upgrades & Downgrades
| Initiated | Mizuho: Neutral | 4/10/2025 |
| Downgrade | Morgan Stanley: Overweight to Equal-Weight | 3/5/2025 |
| Downgrade | Citigroup: Buy to Neutral | 3/4/2025 |
| Maintains | Goldman Sachs: Neutral to Neutral | 3/3/2025 |
| Downgrade | Wells Fargo: Overweight to Equal-Weight | 3/3/2025 |
| Maintains | Barclays: Overweight to Overweight | 2/28/2025 |